Skip to content

T +27 (0)21 900 6277
E reception@haemalife.co.za

A 4G Riverside View Chambers
Netcare Kuils River Hospital
33 Van Riebeeck Road
Kuils River
7580


About Us

HISTORY

Our Story

Haemalife began as the brainchild of two friends brought together by their passion for haematology. They shared a common goal: to save lives and make a difference. The dream of Pieter De Witt and Hannes Koornhof became a reality when Haemalife opened its doors in 2015. The first stem cell transplant was successfully performed on the 3rd of February 2016 in our Bone Marrow Transplant Unit at Netcare Kuils River Hospital. In 2015 Haemalife consisted of just 3 staff members. Today we are a large practice with multiple facets enabling us to offer holistic care.

We understand that patients have individual needs and our team is dedicated to ensuring that every patient that walks through our doors receives precision, personalised therapy. Care of a high standard given by our doctors, nurses, and support staff is our first priority. We endeavour to treat all patients and their loved ones with compassion, understanding and professionalism.

EXCELLENCE AND COMPASSIONATE CARE

What do we stand for?

Our Principles

Haemalife’s core values are inspired by the calibre of our employees, along with their experience, expertise, professionalism and deeply held beliefs. This forms the fundamental driving force that shapes our Company Culture.

Vision

Haemalife is dedicated to patient-centricity and to offering the most advanced therapies available worldwide to our patients in South Africa.
Read More

Mission

Creating access to comprehensive haematology services and care in a safe and compassionate environment.
.
Read More

Core Values

Our values are inspired by the calibre of our employees, along with their experience, expertise, professionalism and deeply held beliefs.
Read More

Company Culture

We strive to treat our patients and team members with respect. We approach our tasks with creativity and resourcefulness. Respect for privacy is a priority.
Read More

Powered by
►
Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.
None
►
Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.
None
►
Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.
None
►
Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.
None
Powered by

VISION

Team Haemalife is dedicated to making a difference and to offer the most advanced treatment methods available worldwide.

Our Haematology services focus primarily on the treatment of haematological malignancies such as leukemia, lymphoma, and myeloma by means of chemotherapy, novel therapies, and bone marrow stem cell transplants.

We pride ourselves in our quality and the standard of care given by doctors, nurses and support staff. We treat all our patients and their families with professionalism, compassion and understanding, and we aim to provide the most effective treatments and support.

MISSION

  • To provide the most advanced and comprehensive haematology services and care in a safe and compassionate environment.
  • To further the understanding, diagnosis, treatment and prevention of disorders affecting the blood and bone marrow, by promoting research, education, clinical care, training and advocacy in haematology in South Africa.
  • To provide quality, accountability and innovation in all our endeavors.
  • To provide continuity of care through the recruitment and retention of the highest quality healthcare professionals and the continuous development and training of our staff and support staff/nurses.
  • Providing a nurturing environment for patients, their families and staff.
  • Paying uncompromising attention to treatment precision and accuracy in all practices/activities.
  • Protect the quality of the environment and meet all challenges with perseverance and dedication.
  • We endeavor to improve the quality of life of patients and their families facing the problems associated with life-threatening illnesses.

CORE VALUES

  • Trust
  • Respect
  • Integrity
  • Care
  • Excellence
  • Passion

Haemalife’s core values are inspired by the quality of our employees, along with their experience, expertise, professionalism and deeply held beliefs, which forms the fundamental driving force and are the powerful shapers of our Company Culture.

Haemalife created an irresistible opportunity for a special, hand-picked few, to call this life changing experience, a job. It nourishes your soul with a deep sense of meaning.

COMPANY CULTURE

  • Treat ourselves and our customers with respect.
  • Be creative and resourceful.
  • Respect data and make human decisions.
  • Be open to change and maintain flexibility.
  • Celebrate and enjoy the journey.
  • Teamwork – we work together, across boundaries, to meet the needs of our patients.
  • Personal accountability – we are personally accountable for delivering on our commitments.
  • Embrace and drive change.
  • Pursue growth and learning.
  • Be humble.
  • Respect for people – We value our people, encourage their development and reward their performance.
  • Be passionate and determined.
  • Diversity – Cultivating a diverse and inclusive work environment.

CLL

Chronic Lymphocytic Leukemia (CLL) is a slow-growing cancer of B-lymphocytes, a type of white blood cell. In CLL, abnormal B-cells accumulate in the blood, bone marrow, and lymphoid tissues, often crowding out healthy cells and weakening the immune system.

Diagnosis is made through blood tests showing a high number of mature-looking lymphocytes, flow cytometry to confirm their identity, and sometimes bone marrow biopsy. Genetic testing helps predict disease course and guide treatment.

Types of CLL are classified mainly by genetic features (e.g., deletions of 17p, 13q, or mutations like TP53) and immunoglobulin heavy chain (IGHV) mutation status, which influence prognosis and therapy choice.

Treatment options depend on symptoms, disease progression, and risk factors. Many patients are initially monitored without treatment (“watch and wait”). When therapy is needed, options include targeted therapies (BTK inhibitors, BCL2 inhibitors), chemotherapy, monoclonal antibodies, and in select cases, stem cell transplantation. Supportive care focuses on managing infections and other complications.

MYELOMA

Multiple Myeloma (MM) is a cancer of plasma cells, a type of white blood cell that produces antibodies. In MM, abnormal plasma cells accumulate in the bone marrow, crowding out healthy cells and producing defective antibodies, which can cause organ damage.

Diagnosis involves blood tests (showing abnormal proteins or anemia), urine tests (detecting excess light chains), and a bone marrow biopsy. Imaging like X-rays, MRI, or PET/CT scans can detect bone lesions. Additional tests identify genetic changes that affect prognosis.

Types of Myeloma are often classified based on the type of abnormal protein produced (IgG, IgA, light-chain, etc.) and genetic features of the plasma cells. Smoldering (asymptomatic) myeloma is an early, slow-growing form.

Treatment options depend on age, health, and disease stage. Common approaches include chemotherapy, targeted therapies (like proteasome inhibitors or immunomodulators), immunotherapy (monoclonal antibodies), stem cell transplantation, and supportive care to manage bone disease, anemia, or kidney problems.

ALL

Acute Lymphoblastic Leukemia (ALL) is a fast-growing cancer of the blood and bone marrow in which immature lymphoid cells (B or T lymphocytes) multiply uncontrollably, crowding out normal blood cells and impairing immune function.

Diagnosis involves blood tests showing abnormal lymphoblasts, followed by a bone marrow biopsy. Immunophenotyping, cytogenetic, and molecular testing are used to confirm the diagnosis, classify the subtype, and assess prognosis.

Types of ALL are classified based on the lymphocyte involved (B-cell or T-cell ALL) and specific genetic abnormalities. Certain subtypes, such as Philadelphia chromosome–positive ALL, have important treatment implications.

Treatment options depend on age, risk factors, and genetic findings. Therapy typically includes multi-phase chemotherapy, targeted therapies (such as tyrosine kinase inhibitors), immunotherapy (including monoclonal antibodies or CAR T-cell therapy), and in some cases stem cell transplantation. Supportive care is essential throughout treatment.

AML

Acute Myeloid Leukemia (AML) is a fast-growing cancer of the blood and bone marrow in which abnormal myeloid cells multiply and crowd out normal blood cells, leading to anemia, infections, and bleeding.

Diagnosis is made through blood tests showing abnormal cells, followed by a bone marrow biopsy. Additional tests such as cytogenetic, molecular, and immunophenotyping studies help confirm AML and guide treatment.

Types of AML are classified based on cell appearance and genetic changes. Major systems include the WHO and FAB classifications. Subtypes are defined by specific chromosome or gene abnormalities, such as acute promyelocytic leukemia (APL), which requires specialized therapy.

Treatment options depend on patient age, health, and AML subtype. They may include intensive chemotherapy, targeted therapies (such as FLT3 or IDH inhibitors), immunotherapy, and stem cell (bone marrow) transplantation. Supportive care, including antibiotics and blood transfusions, is also essential.